Company intelligence / Profile preview
Cayuga Biotech
Basking Ridge, New Jersey, United Statescayugabiotech.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Preclinical data shows their polyP-SNP (silica nanoparticle) complex generated thrombin 12 times faster than control, resulting in faster clotting with low potential for off-target thromboembolism. The therapy demonstrated ability to overcome conditions known as the "lethal triad"—hemodilution, acidemia, and hypothermia—which are associated with poor survival after injury with hemorrhage[6].
- Therapeutic areas
- Hematology
- Modalities
- Small molecule drugsChemical drugsBiomimetic polyphosphate-based therapies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Cayuga Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cayuga Biotech.